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contralateral cancers in lung, breast or kidney] *Table shows 
higher proportions of older patients over time in an area with 
many male smokers in the past and (too) many female 
smokers in the near future. 
The clinical dilemmas are often delineated as lack of 
evidence-based guidelines but are the consequence of 
aspects like: host heterogeneity by increasing (with age) 
presence of co-morbidities at diagnosis, social support and 
distance to radiotherapy, and degree of subspecialization 
(often introduced by younger collegues) and technical and 
communicational infrastructure for consultation, 
protocllization,and consensus building; this not just implies 
absence of guidelines or randomised research, but also 
inadequate observational research of more less selected 
patients. In fact complex patients with clinical dilemmas are 
the raison d'étre for doctors versus robots. With respect to 
3rd line radiotherapy, there are by definition selections in 
referral by the various surgeons, also varying by hospital of 
diagnosis and primary surgical or hematologic treatments. 
Intriguingly (certainly for patients) both synergy and 
competition between the various modalities which is a major 
rationale for multi-disciplinary consultations. Given all these 
and even with perfect knowledge which often become rituals 
in case of too much routine. 
In the presentation several data will be presented on 
variation in referral whereby co-morbidity plays a role in 2 
directions: higher referral rates for curative treatment in 
case of more co-morbidity, radiotherapists seeing patients 
with a worse prognosis or lower referral rates in case of 
adjuvant therapies administered to patients with serious co-
morbidity at older age. 
But observational studies of prognosis and other outcomes (in 
fact throughcomes) also need to be devised with a 
hypothesis, because otherwise too many doctors will end up 
in the datacemetery, buried by their own big data 
collections. Thereby also discerning two major categories of 
older patients: 1. the troisieme age group of between 60 and 
80 years with modest serious co-morbidity and in principle 
(yes, unless....) following the guidelines based on clinical 
trials etc. 2. the (proto)frail vulnerable group over 75 - 80 
years who in fact do not qualify any more for the usual 
aggressive and toxic oncological therapies, unless enough 
arguments can be found for (and by) that patient, including a 
gamble. The research strategy consists of seeking for 
information which may make clear either what the benefits 
and/or harms will be of potential overtreatment versus of 
undertreatment like higher locoregional recurrence rates. 
But comparative interpretation of such data might only be 
meaningful when such analyses are done on population-based 
series of patients in order to have the unfererred patients in 
the picture. And the unreferral rates usually increase with 
age. 
In the South of the Netherlands we also paid attention to 
potentially increasing referral rates to radiotherapy by 
making GP's more aware of the possibilities of fast track 
radiotherapy for symptoms after we found out that most GPs 
indicated to have had minimal (post)graduate education in 
radiotherapy. 
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The ideal radiation detector does not exist however knowing 
the characteristics of each of the detectors available will 
allow us to choose the most appropriate for a particular dose 
measurement. During the last years due to the 
implementation of new techniques and technologies new 
detector systems have been commercialized in order to 
guarantee safe treatment delivery. This talk will review  the 
physical principles of operation of different commercial 
detectors  and how they can be used for reference and 
relative dose measurements in high energy x-ray beams. 
Point detectors such as ion chambers, diamonds, diodes, 
MOSFET and scintillators will be described focusing in their 
strengths and limitations. Considerations on when and how 
these detectors should be used will be given. I will also cover 
briefly 2D measurements using point detectors arrays and 
radiochromic films.  
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In developed countries more than half of all cancer patients 
receive radiotherapy at some stage in the management of 
their disease. However, a radiation induced secondary 
malignancy can be the price of success if the primary cancer 
is cured or at least controlled.  
With the application of new radiation treatment modalities 
such as intensity modulated radiotherapy, intensity 
modulated arc-therapy, proton and heavy ion radiotherapy 
increased cancer cure rates are expected. However, with the 
application of these treatment techniques also a larger 
number of secondary cancers is expected. Some workers 
believe that we will see an increase in second malignancies 
due to the substantial increase in beam-on time of IMRT 
techniques to deliver the same target dose and the different 
distribution of dose (“low dose to a large volume”) compared 
to conventional treatment techniques. In addition, during 
proton and heavy ion radiotherapy neutrons are created and 
could also have an impact on secondary cancer incidence. 
Therefore it could be of great importance to know the risk 
for the patient to develop a cancer which could have been 
caused by the radiation treatment.  
The long term risks from modern radiotherapy treatment 
techniques have not yet been determined and are unlikely to 
become apparent for many years, due to the long latency 
time for solid tumor induction. Therefore there is a need to 
develop models for risk assessment based on the current 
knowledge of radiation induced carcinogenesis. 
The current knowledge of the shape of the dose-response 
curve for radiation induced cancer for doses larger than a 
few Gy is reviewed. In patients who receive radiotherapy, 
parts of the patient volume can receive high doses of up to 
approximately 100 Gy and it is therefore of great importance 
to know the dose-response curve of the risk for the patient to 
develop a cancer which could have been caused by the 
radiation treatment. These dose-response curves are then 
used to model second cancer induction for radiotherapy 
patients based on the three-dimensional dose distribution of 
the treatment of the primary disease. Current models used 
for such risk estimates are reviewed. 
The three-dimensional dose distributions including the 
peripheral dose on which the risk modeling is based on is 
reviewed for different linear accelerators and treatment 
techniques. In addition the neutron dose of photon and 
proton treatments is analysed. In the figure the neutron dose 
equivalent of passive proton therapy (dotted line) is plotted 
as a function of the distance from the isocenter for a 
adolescent patient who was treated for a rabdomyosarcoma 
in the prostate. In comparison the photon scatter dose for a 
3DCRT 6 MV treatment plan (solid line) and the neutron dose 
equivalent of 3DCRT 15 MV (dashed line) therapy is plotted. 
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Technological advances combined with increasing knowledge 
about the natural course of malignant diseases progressed 
enormously over the last decades. Improved RT-techniques 
were, remarkably, only relatively late introduced for 
treatment of malignant lymphoma and breast cancer, two 
disease sites where excellent results with a high cure rate 
and thereby a high demand to avoid long term toxicity are 
obtained. Especially in breast cancer, still today some 
departments do not properly delineate target volumes and/or 
continue to use rather basic RT-techniques. 
ESTRO published a consensus guideline for target volume 
delineation in breast cancer that was developed in five years 
of work, after obtaining a broad consensus agreement of the 
RT-community. The next step is now to introduce volume 
contouring in agreement with these guidelines on a routine 
base. Personal experience is that, after proper training, it 
can be done in a very reliable and little time consuming 
manner. It could also be appropriate to involve, to train and 
involve RTT for doing this under the responsibility of the 
radiation oncologist. The downloadable as well as online 
available fully contoured cases will greatly facilitate this. 
Many RT-techniques have been described and are in use, 
often based on older standard techniques that are adapted 
and optimized to improve dose homogeneity, treatment 
positioning or treatment time, while others are based on new 
technical developments. For sure, the optimal technique for 
all patients does simply not exist and the most appropriate 
setup should be chosen based on a combination of the 
